In an interview with PharmaShots, Dr. Bob Deans, Chief Scientific Officer at Synthego shares insights on the wide availability of its new CRISPR-based platform, Eclipse. Synthego created the Eclipse platform […]readmore
Tags : Drug Discovery
Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, […]readmore
Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration […]readmore
Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with […]readmore
Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a […]readmore
Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the […]readmore
Shots: Genesis to receive an up front and is eligible to receive pre/ clinical and regulatory milestones along with royalties on sales of approved drugs emerges from the collaboration The […]readmore
Shots: Schrodinger expands its work to discover novel antiviral therapies for COVID-19 as a part of a philanthropic global initiative. The accelerated pace includes the evaluation of billions of molecules/ […]readmore
Shots: RGC and CCPM to create genomics database of 450,000 DNA samples and corresponding health record from de- identified patients who participated in UCHealth system, and will sequence the DNA […]readmore
Shots: The collaboration will utilize Insilico’s generative ML technology and Pandomics discovery platform to identify potential therapeutic targets implicated in multiple diseases Insilico’s Pandomics platform will foster Boehringer’s capabilities to […]readmore